Using a radioactive chromium technique, McLean Baird (personal communication, 1972) has shown that the mean daily blood-loss of 1 16 ml. during Alclofenac administration in a dosage of 3 g. daily was not significantly different from control periods; by comparison, the same volunteers treated with 3-6 g. daily of soluble aspirin had a mean daily blood-loss of 4-14 ml. which was significantly greater than that during Alclofenac treatment and control periods. Preliminary clinical studies of Alclofenac in patients with rheumatoid arthritis have suggested that the drug has clinically useful analgesic and anti-inflammatory properties and a low incidence of side-effects (Ory, 1971; Aylward and Davies, 1972; Pavelka, Vojti §ek, Bremova', Kainkova' and Handlova, 1973; Aylward, 1973) .
In view of the potential advantage to patients with rheumatoid disease of an effective analgesic/antiinflammatory drug which causes insignificant gastrointestinal bleeding, it was decided to undertake a study of Alclofenac and aspirin to compare the clinical efficacy of the two drugs and to monitor several haematological, serological, and biochemical parameters during the course of 17 weeks' continuous administration of each drug to matched groups of patients.
Method PATIENTS 52 patients with classical or definite rheumatoid arthritis (Ropes, Bennett, Cobb, Jacox, and Jessar, 1959 ) entered the trial; 26 were to receive aspirin and 26 Alclofenac. Ten patients were subsequently withdrawn from the study: four from the aspirin group because of persistent indigestion, two from the Alclofenac group because of the appearance of a rash, two from the aspirin group because of symptoms of salicylism, and one from each group because of lack of analgesia. This left 23 patients in the Alclofenac group and nineteen in the aspirin group.
The characteristics of each group (shown in Table I ) were found to be comparable.
Patients were excluded if they had any history of intolerance to either of the trial agents, or had received steroids, gold salts, or chloroquine within the previous year. Pregnancy was excluded in those of child-bearing age by testing the urine at fortnightly intervals with the 'prepurex test.' DOSAGE The drugs were administered as identical capsules and the patients were allocated to one of the treatment schedules according to a predetermined random code. The daily dosage of aspirin was 4-8 g. and of Alclofenac 3 g., each being administered in three equal doses per day. No other anti-inflammatory or analgesic agents were allowed and physiotherapy and wax baths were discontinued for the duration of the trial.
Studies on 4-allyloxy-3 chlorophenylacetic acid (Alclofenac) 269 (Aylward and Davies, 1972) .
Articular index
The method of scoring the pain on palpating thejoints on a four-point scale (0-1-2-3) as described by Ritchie, Boyle, McInnes, Jasani, Dalakos, Grieveson, and Buchanan (1968) was used, except that the ankle, talo-calcaneal, and mid-tarsal joints were taken as a single unit, since in several cases of severe inflammation, it was found impossible to differentiate between them.
Laboratory investigations A full blood count and erythrocyte sedimentation rate, blood urea, serum uric acid, serum bilirubin, standard liver function tests, and serum enzymes (SGOT, SGPT, and LDH) were recorded at each visit. Serum immunoglobulin levels were determined by radial immunodiffusion in agar-antibody plates (Behring immunodiffusion plates Hoechst pharmaceuticals, Hounslow, Middlesex). Tests for rheumatoid factor activity were performed after initial heat inactivation at 56°C. for 30 min.; activity was measured at 22°C. using latex particles coated with aggregated human gamma globulin and sheep red cells sensitized with rabbit gamma globulin. Latex-agglutination titres greater than 1: 40 were considered to be abnormal.
Results
The clinical results of the trial are summarized in Table II (overleaf). At each assessment made before the 13th week, both treatments produced an equal reduction in pain scores, in articular index, and in the total number of inflamed joints. Thereafter, to the end of the study, improvement based on the results of these three parameters was significantly greater in the Alclofenac group (Table II) . Improvement in duration of morning stiffness and in grip strength occurred in both groups, but a statistically significant improvement in favour of Alclofenac was attained from the 9th week to the end of the study.
Thioughout the study, there were no significant changes in digital joint size in either group taken as a whole.
In the Alclofenac-treated group, eight patients improved by at least one functional grade during the 17-week treatment period and in no instance was there a deterioration to a more severe grade. This represents a statistically significant change (Wilcoxon signed-rank test: n = 8; P = 0-001 in a one-sided test).
In the aspirin-treated group, six patients improved by at least one functional grade, and one deteriorated by one grade. This does not represent a statistically significant change (Wilcoxon signed-rank test: n = 6; r = 35; P> 0-1 in a one-sided test). Comparison of the measurements of ESR in the two treatment groups at initial assessment and after 17 weeks revealed that the statistically significant difference between the treatment groups after 17 weeks' therapy (P < 0-05) was not present at initial assessment (P > 0 1).
Biochemistry
The serum enzyme investigations showed no regular pattern of change during the trial. The total LDH and SGOT activities were raised in three patients from each group before participating in the trial. In all but one of these (a patient in the aspirin-group) the LDH and SGOT levels returned to normal. In the other patients LDH activity increased after 6 to 8 weeks' treatment in five patients (four receiving aspirin and one receiving Alclofenac). No significant changes were noted in standard liver function tests, blood urea, or serum uric acid.
Rheumatoidfactor titres and serum immunoglobulins 92 per cent. of patients in the trial showed hypergammaglobulinaemia with raised levels of IgG, IgA, and IgM (Table III) . There was no significant difference from baseline values in individual immunoglobulin levels in patients of either group at 9 weeks. At 17 weeks individual serum IgG levels in patients receiving Alclofenac were lower, but the change did not reach statistical significance (Table III: 0-1 > P> 0-05).
However, there was a reduction in serum IgM levels at 17 weeks which just reached statistical significance (P = 0 05). In contrast the aspirin-treated group showed no reduction in levels of IgM or IgG (Table  III) . Comparison of the Alclofenac group with the aspirin group indicated a statistically significant difference in IgM levels at 17 weeks (P < 0 05). Serum IgA levels did not change in any noticeable manner during treatment with either drug.
Analysis of the changes, by a ranking procedure, in latex-agglutination titres during 17 weeks in each treatment group indicated that there was a statistically significant fall in titres in the Alclofenac group, (Wilcoxon signed-rank test: n = 10; r = 0; P = 0 02) which did not occur in the patients treated with aspirin (n = 7; r= 110; P > 0-2).
CORRELATION BETWEEN DISEASE STATE, ESR, AND SEROLOGY
There was a highly significant correlation between the recorded decrease in ESR values and the decline in articular indices after 17 weeks of Alclofenac therapy (D2 + T = 744 00; Spearman's rank correlation test; P < 0-01 Paired-data analysis of IgG change within the Alclofenac-group indicated a reduction at 17 weeks (t = 1-69; 0-1 > P > 0 05). t Paired-data analysis of IgM changes within the Alclofenac group showed a significant reduction at 17 weeks (t = 2 0196; P = 0-05) and difference in IgM levels between treatment groups was significant at 17 weeks (t = 2-127; P < 0 05). change in articular index was not proven in the aspirin-treated group (D2 + T = 601; P > 0 1). In those receiving Alclofenac, the correlation between the decline in IgM levels and the fall in latex titres after 17 weeks of therapy just reached statistical significance (D2 + T = 1,187; P = 0 05).
There was no significant change in sheep cell agglutination titres in either group of patients. (Table IV) There were fewer spontaneous complaints in the Alclofenac group than in the aspirin group. In particular, the frequency of gastrointestinal upset was greater in the aspirin group.
SIDE-EFFECTS

Discussion
The results of the present study have shown that Alclofenac is an effective analgesic for the treatment of active rheumatoid arthritis. A significant antiinflammatory effect of this drug, as measured by a reduction in the erythrocyte sedimentation rate, was also demonstrated. Boardman and Hart (1967) have suggested that a reduction in the circumference of the proximal interphalangeal joints of the hands is a good index of anti-inflammatory effect, but these authors emphasized that this reduction can only be obtained in a relatively small number of patients with active synovitis and reversible joint swelling. A randomly selected group of patients with rheumatoid disease will usually consist of patients who do not fulfil the strict criteria essential for the demonstration of the small but significant change injoint size. In the present study, it was not surprising, therefore, that no significant change in joint size was found in either group of randomly selected patients. The Alclofenac-treated group showed a significantly greater reduction in articular index and in the number of inflamed joints than did the aspirin group. Although both groups experienced an improvement in grip strength and a reduction in the duration of morning stiffness, the improvement on Alclofenac was significantly greater after the ninth week of treatment. Alclofenac produced a significantly greater reduction in the duration of morning stiffness, in the total number of inflamed joints, and in the total articular index than aspirin. At each assessment both groups showed a progressive improvement in overall pain scores and in grip strength; after 9 weeks this improvement was significantly greater for the Alclofenactreated patients. Only in the Alclofenac group was there a significant improvement in functional grade and reduction in erythrocyte sedimentation rate at the end of the trial.
No significant changes were found in either group in total digital joint size.
The study also reports a significant lowering of serum IgM levels and a marked decline in serum IgG levels during the administration of Alclofenac. No such effect was detected in the group of patients receiving aspirin, and neither group exhibited any discernible changes in IgA levels.
The observed decline in serum IgM levels showed significant correlation with a significant fall in latexagglutination titres, but not in sheep cell titre.
The implications ofthe observed reduction in serum IgG and IgM levels during Alclofenac therapy are discussed.
